All In MedTech

Device Trial Radar · NCT07234500

Evaluation of a Mobile Application Designed to Support Type 1 Diabetic Patients in Adjusting Their Insulin Doses.

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Sep 1, 2025

Primary completion

Jun 30, 2026

Study completion Jul 30, 2026

Sponsor

Lead sponsor
University of BaghdadAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Title: Evaluating a Mobile Application for Insulin Management in Iraqi Type 1 Diabetes Patients. The goal of this clinical trial is to determine whether a mobile health application can improve insulin management and blood sugar control in Iraqi patients with Type 1 Diabetes aged over 15 years who are on intensive insulin therapy. The main question it aims to answer is: Does the use of the mobile application lead to a greater reduction in HbA1c levels compared to standard care alone? Researchers will compare the group using the mobile application to the group receiving standard care alone to see if the application is more effective at improving glycemic control. Participants will be assigned to one of two groups for the 3-month study. Either use the mobile application to guide their daily insulin dose adjustments alongside standard care, or receive standard care alone. Undergo blood tests (including HbA1c) and complete questionnaires about hypoglycemic events, insulin adherence, and quality of life.

Conditions

  • Type One Diabetes Mellitus

Interventions

  • mHealth Mobile ApplicationDevice

    This is a culturally and linguistically tailored mobile health (mHealth) application designed for Arabic-speaking patients with Type 1 Diabetes in Iraq. The core function is to assist in calculating precise pre-meal insulin bolus doses by integrating: (1) carbohydrate intake, (2) current blood glucose level, and (3) planned physical activity. Key tailored features include: a database of common Arabic cuisine for easy carbohydrate counting using food photographs (aiding patients with low health literacy), full Arabic language support, and algorithms calibrated for insulin types available in the Iraqi market. The app automatically calculates personalized insulin-to-carbohydrate ratios and correction factors based on the patient's total daily insulin dose, removing the need for manual entry and complex calculations.

  • Standard Care (in control arm)Other

    Routine clinical management for type 1 diabetes, including regular insulin dose adjustments based on standard practice (e.g., clinic visits, HbA1c monitoring).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Hemoglobin (HbA1c)Time frame: Baseline (Day 0) and Post-intervention (Month 3)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Faiha Specialized Diabetes, Endocrine and Metabolism Center at Al-Faiha Teaching hospital

    Basra, Basrah, Iraq

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.